Combining noncoding RNA profiles and HPV genotyping improves cervical cancer risk assessment

A new molecular screening strategy could help doctors distinguish human papillomavirus infections that are likely to disappear from those that may be moving toward cervical cancer, according to a review published in Molecular Biology Reports. The approach combines HPV genotyping with measurements of non-coding RNAs—molecules that do not produce proteins but can exert powerful control over gene activity. By reading both the virus and the host cell, researchers argue, screening could move beyond the simple question of whether high-risk HPV is present and begin to estimate whether an infection is biologically active, persistent and potentially dangerous.

The distinction matters because infection with a high-risk HPV type is common, while cervical cancer is relatively uncommon among infected individuals. Most HPV infections are transient and are cleared by the immune system without causing lasting cellular damage. A smaller proportion persist, and persistent infection can create the conditions for precancerous lesions and, eventually, invasive cancer. Current screening methods—including HPV DNA testing, cytology and visual examination—have improved early detection, but they do not always identify which positive results represent a short-lived infection and which signal a transformation process already underway. This uncertainty can lead to repeated testing, unnecessary procedures or delayed attention to genuinely high-risk disease.

HPV genotyping supplies an important part of the missing information. Rather than reporting only that HPV is present, genotyping identifies the specific viral type or group. Some strains, particularly HPV16 and HPV18, are strongly associated with cervical cancer, while other high-risk types carry different levels of risk. Genotyping is therefore useful for surveillance, triage and evaluating vaccination programs. Yet the viral type alone cannot reveal whether the virus is actively altering the host cell. Two people infected with the same high-risk strain may have very different outcomes, depending on viral persistence, immune responses, viral gene expression and changes accumulating in cervical cells.

The proposed second layer of testing focuses on non-coding RNAs, or ncRNAs. These include microRNAs, long non-coding RNAs and circular RNAs, each with distinct molecular properties and functions. MicroRNAs are short RNA molecules that bind to messenger RNAs and usually reduce the production of specific proteins. Long non-coding RNAs can influence gene transcription, organize protein complexes or alter the stability and availability of other RNAs. Circular RNAs form closed loops that can be unusually resistant to degradation and may regulate gene expression by binding microRNAs or interacting with proteins. Together, these molecules create a regulatory network that can reflect how a cervical cell is responding to HPV.

The biological connection between HPV and ncRNAs is central to the review’s argument. High-risk HPV produces oncoproteins, particularly E6 and E7, that interfere with cellular safeguards governing genome stability, cell division and programmed cell death. E6 can promote the degradation or functional suppression of the tumor-suppressor protein p53, while E7 disrupts the retinoblastoma pathway, which normally restrains inappropriate entry into the cell cycle. These disturbances can reshape the cell’s transcriptional and post-transcriptional programs. In turn, altered ncRNAs may help sustain proliferation, weaken apoptosis, modify immune signaling and promote invasion—features associated with malignant progression.

Several candidate molecules illustrate how such signals might be used. The review discusses microRNAs whose abundance changes in HPV-associated cervical disease, including miR-21, miR-155, miR-375, miR-145 and miR-106b-5p. Some have been linked with enhanced growth, migration or poor prognosis, while others appear to restrain invasion or proliferation and become reduced during disease progression. The molecular effects are not interchangeable: miR-21, for example, has been associated with pathways affecting growth and migration, whereas reduced miR-375 has been linked to loss of control over transcription factor SP1. These patterns could form part of a multi-marker signature rather than serve as stand-alone diagnostic tests.

Long non-coding and circular RNAs may add information about the architecture and persistence of the cancer-associated regulatory network. HOTAIR has been associated with cervical cancer progression and has been studied in serum and vaginal discharge, while MALAT1 can be regulated by the HPV16 E7 protein and has been connected to cancer progression, metastasis, immunity and treatment resistance. Other studies summarized in the review describe HPV-related changes in lnc-FANCI-2 and circular RNAs involved in regulatory axes such as miR-1236-3p/TRIM37 and miR-1179/ABL2. Because circular RNAs are structurally stable and many ncRNAs can circulate in blood or other biological fluids, they are attractive candidates for liquid biopsy tests that might avoid or complement tissue sampling.

In practice, an integrated test could combine several forms of evidence from one sample. HPV DNA analysis would identify the viral genotype, while RNA profiling could measure a panel of host-response molecules and perhaps indicators of active oncogenic signaling. A computational model could then classify a patient’s result into a lower- or higher-risk category, guiding the interval for repeat screening or the need for colposcopy and biopsy. The same principle could potentially be adapted to self-collected vaginal samples, cervical specimens or blood-based assays, although the review does not present a clinically validated test or a new patient cohort. It describes a diagnostic framework whose usefulness depends on selecting robust markers, standardizing laboratory methods and proving that the combined signal predicts outcomes better than existing screening.

That evidence gap is the most important qualification. The authors emphasize that individual ncRNAs have shown promising associations with HPV-mediated carcinogenesis, but evidence for their combined clinical use with HPV genotyping remains limited. Biomarker levels can vary with age, inflammation, hormonal status, sampling technique, disease stage and the composition of the surrounding tissue. Results generated in cell lines or small retrospective studies may not translate directly to diverse populations or routine clinics. Prospective studies will need to follow HPV-positive individuals over time, compare transient and persistent infections, test different viral genotypes and establish thresholds that are reproducible across laboratories. The review also notes that no datasets were generated or analyzed for the study itself, because it is a narrative synthesis of existing evidence.

If validated, the strategy could make cervical screening more precise without replacing established prevention tools. HPV vaccination remains fundamental, and conventional HPV testing and cytology remain valuable for identifying people who need further assessment. The promise of ncRNA profiling is to add biological context: not only which virus is present, but how strongly it is influencing the host cell. Such information could reduce the burden of unnecessary follow-up while directing clinical attention toward infections with molecular signs of transformation. For now, the concept is best viewed as an emerging precision-screening platform rather than a ready-to-use diagnostic. Its viral-news appeal lies in a simple idea with complex biology: the future of cervical cancer detection may depend on listening simultaneously to the genome of the virus and the regulatory RNA language of the cell it infects.